Fast-Track proposals will not be accepted.
Number of anticipated awards: 1
Budget (total costs):
It is strongly suggested that proposals adhere to the above budget amounts and project periods. Proposals with budgets exceeding the above amounts and project periods may not be funded.
This solicitation is for the development of conjugates between specific antibodies or protein A with microccocal nuclease (MNase) to be used for genome-wide epigenetic mapping. They will be used to identify genome-wide epigenetic changes during normal development and pathological conditions, requiring only a few hundred primary or patient cells.
The project goal is to develop reagents that can be used for mapping genome-wide epigenetic changes during normal development and disease process in rare primary and patient cells. Because conjugating proteins could result in inactivation of the proteins, it will be important to achieve efficient conjugation between antibodies and MNase while reserving the activities of both.
Phase I Activities and Expected Deliverables
Specific deliverables are:
It is critical that the developer provide evidence to show that the antibodies in the conjugates are still specific and as active as non-conjugated antibody using Western and ChIP assays. It is critical that the MNase in the conjugates is still as active as non-conjugated MNase using chromatin digestion assay. It is critical that the free individual proteins (un-conjugated) in the final products are less than 5% of all protein components.